Alnylam Begins Phase I Trial of TTR Amyloidosis Drug

The study is being conducted in Portugal, Sweden, and the UK and will enroll about 28 patients with the disease.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.